

Optimizing care for patients with Fabry disease: Interactive case challenges

Chair

Anjay Rastogi, MD, PhD, UCLA David Geffen School of Medicine, UCLA Health, Los Angeles, CA, USA

Faculty

Dawn J. Laney, MS, CGC, CCRC, Emory University School of Medicine, Atlanta, GA, USA

John L. Jefferies, MD, MBA, MPH, FACC, FAHA, FAAP, FHFA, FESC, FRCPE, University of Memphis School of Public Health, American College of Cardiology, and American Heart Association, Memphis, TN, USA

Release date: June, 2024

Expiration date: June, 2025

Estimated time to completion: 1 hour

Available Continuing Medical Education (CME) credits: This activity is approved for 1 AMA PRA Category 1 Credit(s)[™].

Activity description

This symposium will provide an interactive, patient-focused learning experience on the multidisciplinary management of patients with Fabry disease, a rare multisystemic lysosomal storage disorder resulting from α -galactosidase A (α -Gal A) deficiency leading to progressive accumulation of globotriaosylceramide (Gb3) in diverse tissues and organs, including the heart and kidneys. During the symposium you will hear patients' personal experiences and be involved in a lively exchange between leading experts and the audience. The clinical journey from diagnosis to treatment will be analyzed, and best practices for multidisciplinary management will be discussed. Furthermore, the experts will review the latest clinical evidence on novel therapies and provide perspectives on treatment strategies.

Target audience

This activity has been designed to meet the educational needs of geneticists and genetic counselors, and other healthcare professionals (HCPs) providing comprehensive diagnostic and therapeutic management and counseling services for patients with, or at risk for, Fabry disease.

Educational objectives

After completing this activity, the participant should be better able to:

- **Identify** early signs of the multisystemic manifestations of Fabry disease and apply guideline-recommended criteria and testing algorithms, including screening of at-risk relatives
- **Evaluate** available clinical data on Fabry disease-specific disease-modifying therapies to support evidence-based treatment decisions

- **Develop** and implement comprehensive (multidisciplinary, interdisciplinary, integrated) care plans to manage potential disease complications, using organ-specific biomarkers and quality of life (QoL) measures, for disease monitoring

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of *1 AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



ABIM-MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to *1 MOC points* in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College of Physicians and Surgeons of Canada

Through an agreement between the Accreditation Council for Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in support of MOC" program in section 3 of the Royal College's MOC Program.

Method of participation and request for credit

There are no fees for participating in, and receiving CME/CE credit for, this activity.

In order to claim credit, participants must complete the following procedures:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. Take the pre-activity test
3. View the expert discussion
4. Take the post-activity test and complete the evaluation

5. Download the certificate of CME credit

Disclosure of conflicts of interest

The Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty	Nature of relationship
Anjay Rastogi	<p>Grant/Research support Anylam Pharmaceuticals, AstraZeneca, Bayer, GlaxoSmithKline, Idorsia Pharmaceuticals, Kadmon Corporation LLC, National Institutes of Health (NIH), Novo Nordisk, Omers, Paladio Group</p> <p>Speakers bureau/Honoraria for non-CME Amgen, AstraZeneca, Aurinia, Bayer, Baxter, Fresenius Medical Care, Sanofi, Vifor Pharma, Natera</p> <p>Consultant/Advisory board Akebia, Amicus, Ardelyx, AstraZeneca, Aurinia, Chiesi Global, Inc., Chinook Therapeutics, Fresenius Medical Care, Vifor Pharma, GlaxoSmithKline</p>
Dawn J. Laney	<p>Grant/Research support Amicus Therapeutics, Sanofi Genzyme</p> <p>Consultant/Advisory board Amicus Therapeutics, Chiesi, Sanofi Genzyme, Takeda</p> <p>Non-mutual funds stock ownership/Stock options ThinkGenetic, Inc.</p>
John L. Jefferies	<p>Employee/Owner Bristol Myers Squibb</p> <p>Grant/Research support Amicus, Chiesi, NIH, Sanofi Genzyme</p> <p>Speakers bureau/Honoraria for non-CME</p>

	<p>Bristol Myers Squibb, Daxor, Nuwellis, NS Pharma, Sanofi Genzyme</p> <p>Consultant/Advisory board Amicus, Chiesi, Daxor, Medtronic, Nuwellis, Pfizer, Rocket Therapeutics, Sanofi Genzyme</p>
--	--

Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.



Financial support

This activity is supported by an independent educational grant from Amicus Therapeutics Inc.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labelled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

Sarita Cappello, Ology Program Manager
info@ologyeducation.org, www.ologyeducation.org

Chantel Crowl, Program Manager
inquiries@pimed.com, www.pimed.com

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Policy on privacy and confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Media

Internet